Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?

OBJECTIVE: To compare drug discontinuation risk between adalimumab (ADA) and etanercept (ETN) treatment among anti-tumor necrosis factor (anti-TNF)-naïve rheumatoid arthritis (RA) patients, in particular the influence of concomitant dose of methotrexate (MTX). METHODS: This retrospective nationwide...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hsin-Hua, Chen, Der-Yuan, Chen, Yi-Ming, Tang, Chao-Hsiun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751906/
https://www.ncbi.nlm.nih.gov/pubmed/26917952
http://dx.doi.org/10.2147/PPA.S94396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751906/
https://www.ncbi.nlm.nih.gov/pubmed/26917952
http://dx.doi.org/10.2147/PPA.S94396

Ejemplares similares